Clinical Trial Update: Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A phase 2 trial evaluated gefitinib with or without tamoxifen in patients with tamoxifen-resistant metastatic breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)
• Tamoxifen (Nolvadex) (Tamoxifen)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED